Back to results
US 2026/0085115 A1Published application
Cd3 binding antibodies
AssigneeTeneoBio, Inc.
InventorsNathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
Life of this patent
Estimating the term…
Abstract
The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
Claims4
-37. (canceled)
A method for treating a disease or condition, comprising administering to an individual in need of an effective dose of a multispecific antibody comprising:
- (i) a first binding moiety that has binding specificity for human CD3δε, comprising:
- (i) a heavy chain variable domain comprising:
- A) a CDR1 sequence comprising GFTFDDYA (SEQ ID NO:
- 29), a CDR2 sequence comprising ISWNSGSI (SEQ ID NO:
- 24), and a CDR3 sequence comprising AKDSRGYGDYRLGGAY (SEQ ID NO:
- 41);
- or
- B) a CDR1 sequence comprising GFTFHNYA (SEQ ID NO:
- 34), a CDR2 sequence comprising ISWNSGSI (SEQ ID NO:
- 24), and a CDR3 sequence comprising AKDSRGYGDYSLGGAY (SEQ ID NO:
- 43);
- and
- C) a light chain variable domain comprising a CDR1 sequence comprising QSVSSN (SEQ ID NO:
- 35), a CDR2 sequence comprising GAS, and a CDR3 sequence comprising QQYNNWPWT (SEQ ID NO:
- 45);
- and
- (ii) a second binding moiety that has binding specificity for a tumor-associated antigen (TAA) or a tumor-specific antigen (TSA).
14 more elements
The method of claim 39, wherein the disease is an autoimmune disease.
Dependencies are inferred from the claim text.